Indie Asset Partners, LLC Editas Medicine, Inc. Transaction History

Indie Asset Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$39.27 - $72.94 $149,226 - $277,172	-3,800 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $118,902 - $215,232	3,800 New	3,800 $215,000
Q1 2021 May 13, 2021	SELL	$39.71 - $90.58 $117,144 - $267,211	-2,950 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$27.07 - $84.35 $79,856 - $248,832	2,950 New	2,950 $207,000

252

58.7M

494K

417K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $234M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Indie Asset Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indie Asset Partners, LLC with notifications on news.